Tempest to Detail 100% CR in Six rrMM Patients at ISCT
Tempest will present REDEEM-1 Phase 1/2a data from TPST-2003 at the ISCT Annual Meeting, reporting a 100% complete response rate among six efficacy-evaluable rrMM patients and a favorable safety profile. Results in patients with extramedullary disease highlight the potential of its CD19/BCMA dual-targeting CAR construct to improve outcomes in rrMM.
1. Clinical Data Highlights
Tempest’s TPST-2003 achieved a 100% complete response rate among six efficacy-evaluable relapsed/refractory multiple myeloma patients in the REDEEM-1 Phase 1/2a study, with no dose-limiting toxicities observed and a favorable safety profile across all cohorts.
2. REDEEM-1 Trial Design
REDEEM-1 is a multicenter, open-label Phase 1/2a trial enrolling 29 patients with rrMM, including those with high-risk cytogenetics and extramedullary disease, evaluating safety, dosing and efficacy of the CD19/BCMA dual-targeting CAR-T candidate.
3. Dual-Targeting CAR Architecture
TPST-2003 employs a parallel-structure CAR targeting both BCMA and CD19 antigens to address tumor heterogeneity and antigen escape, aiming to deepen response duration and prevent relapse in multiple myeloma patients.
4. Presentation and Next Steps
Data will be presented at the ISCT Scientific Annual Meeting in Dublin on May 6–9, with an oral presentation and poster session; Tempest plans to replicate these results in the remainder of REDEEM-1 and pursue a registrational trial outside China.